Rigel Pharmaceuticals Stock Alpha and Beta Analysis
| RIGL Stock | USD 21.57 0.71 3.40% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Rigel Pharmaceuticals. It also helps investors analyze the systematic and unsystematic risks associated with investing in Rigel Pharmaceuticals over a specified time horizon. Remember, high Rigel Pharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Rigel Pharmaceuticals' market risk premium analysis include:
Beta 2.52 | Alpha 0.0806 | Risk 4.63 | Sharpe Ratio (0.02) | Expected Return (0.1) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Rigel |
Rigel Pharmaceuticals Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Rigel Pharmaceuticals market risk premium is the additional return an investor will receive from holding Rigel Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Rigel Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Rigel Pharmaceuticals' performance over market.| α | 0.08 | β | 2.52 |
Rigel Pharmaceuticals expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Rigel Pharmaceuticals' Buy-and-hold return. Our buy-and-hold chart shows how Rigel Pharmaceuticals performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Rigel Pharmaceuticals Market Price Analysis
Market price analysis indicators help investors to evaluate how Rigel Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Rigel Pharmaceuticals shares will generate the highest return on investment. By understating and applying Rigel Pharmaceuticals stock market price indicators, traders can identify Rigel Pharmaceuticals position entry and exit signals to maximize returns.
Rigel Pharmaceuticals Return and Market Media
The median price of Rigel Pharmaceuticals for the period between Wed, Nov 20, 2024 and Tue, Feb 18, 2025 is 21.65 with a coefficient of variation of 17.09. The daily time series for the period is distributed with a sample standard deviation of 3.66, arithmetic mean of 21.39, and mean deviation of 3.05. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | How Much Upside is Left in Rigel Wall Street Analysts Think 28.28 | 11/19/2024 |
2 | Acquisition by Raul Rodriguez of 300000 shares of Rigel Pharmaceuticals at 1.87 subject to Rule 16b-3 | 11/22/2024 |
3 | Acquisition by Schorno Dean L of 6250 shares of Rigel Pharmaceuticals at 18.7 subject to Rule 16b-3 | 11/25/2024 |
4 | Acquisition by Moos Walter H of 30000 shares of Rigel Pharmaceuticals at 0.9075 subject to Rule 16b-3 | 11/26/2024 |
5 | Lacklustre Performance Is Driving Rigel Pharmaceuticals, Inc.s 28 percent Price Drop | 12/20/2024 |
6 | Acquisition by Raul Rodriguez of 400000 shares of Rigel Pharmaceuticals subject to Rule 16b-3 | 12/27/2024 |
7 | Rigel to Present at the 43rd Annual J.P. Morgan Healthcare Conference | 01/08/2025 |
8 | Rigel Upgraded to Buy Heres Why | 01/15/2025 |
9 | Wall Street Analysts Predict a 75.79 percent Upside in Rigel Heres What You Should Know | 01/17/2025 |
10 | Disposition of 45000 shares by Raul Rodriguez of Rigel Pharmaceuticals at 21.4 subject to Rule 16b-3 | 01/24/2025 |
11 | Acquisition by Furey Raymond J. of 14788 shares of Rigel Pharmaceuticals at 22.49 subject to Rule 16b-3 | 01/29/2025 |
12 | Does Rigel Have the Potential to Rally 40.88 percent as Wall Street Analysts Expect | 02/03/2025 |
13 | Disposition of 1448 shares by Furey Raymond J. of Rigel Pharmaceuticals at 20.921 subject to Rule 16b-3 | 02/04/2025 |
14 | Disposition of 13 shares by Furey Raymond J. of Rigel Pharmaceuticals at 21.926 subject to Rule 16b-3 | 02/05/2025 |
15 | Will Lower Commercial Premiums Hurt Humanas Q4 Earnings | 02/07/2025 |
16 | Rigel Pharmaceuticals CFO Dean Schorno sells 80,614 in stock - MSN | 02/11/2025 |
About Rigel Pharmaceuticals Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Rigel or other stocks. Alpha measures the amount that position in Rigel Pharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2024 | 2025 (projected) | Graham Number | 7.97 | 8.4 | 7.98 | Receivables Turnover | 2.98 | 3.44 | 3.27 |
Rigel Pharmaceuticals Upcoming Company Events
As portrayed in its financial statements, the presentation of Rigel Pharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Rigel Pharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Rigel Pharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Rigel Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Rigel Pharmaceuticals' management manipulating its earnings.
| 5th of March 2024 Upcoming Quarterly Report | View | |
| 7th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 5th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Rigel Pharmaceuticals
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Rigel Pharmaceuticals Backtesting, Rigel Pharmaceuticals Valuation, Rigel Pharmaceuticals Correlation, Rigel Pharmaceuticals Hype Analysis, Rigel Pharmaceuticals Volatility, Rigel Pharmaceuticals History and analyze Rigel Pharmaceuticals Performance. For more information on how to buy Rigel Stock please use our How to buy in Rigel Stock guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Rigel Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.